Regulatory T Cells Negatively Affect IL-2 Production of Effector T Cells through CD39/Adenosine Pathway in HIV Infection

PLoS Pathogens

Volumn 9, Issue 4, 2013, Pages

  Jenabian, Mohammad Ali ^a,b   Seddiki, Nabila ^a,b,c   Yatim, Ahmad ^a,b   Carriere, Matthieu ^a,b   Hulin, Anne ^d   Younas, Mehwish ^a,b   Ghadimi, Elnaz ^e   Kök, Ayrin ^a,b   Routy, Jean Pierre ^f   Tremblay, Alain ^g   Sévigny, Jean ^g   Lelievre, Jean Daniel ^a,b,c,d   Levy, Yves ^a,b,c,d  

^a INSERM   (France)

^b FACULTÉ DE MÉDECINE   (France)

^c Vaccine Research Institute   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e MCGILL UNIVERSITY   (Canada)

^f MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^g LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; ADENOSINE RECEPTOR; ADENOSINE TRIPHOSPHATASE; CD39 ANTIGEN; CELL PROTEIN; CYCLIC AMP; INTERLEUKIN 2; MESSENGER RNA;

ARTICLE; CD4+ T LYMPHOCYTE; CELL ISOLATION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; DEMETHYLATION; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; PROMOTER REGION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

5'-NUCLEOTIDASE; ADENOSINE; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; APYRASE; CELL PROLIFERATION; CYCLIC AMP; DNA METHYLATION; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; PROMOTER REGIONS, GENETIC; RECEPTOR, ADENOSINE A2A; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84876851056     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003319     Document Type: Article

References (63)

1. Vignali DA, Collison LW, Workman CJ, (2008) How regulatory T cells work. Nat Rev Immunol 8: 523-532.
2. Fehervari Z, Sakaguchi S, (2004) Development and function of CD25+CD4+ regulatory T cells. Curr Opin Immunol 16: 203-208.
3. O'Garra A, Vieira P, (2004) Regulatory T cells and mechanisms of immune system control. Nat Med 10: 801-805.
4. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, et al. (2006) CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 203: 1701-1711.
5. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, et al. (2006) Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 203: 1693-1700.
6. Weiner HL, (2001) Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 182: 207-214.
7. Vieira PL, Christensen JR, Minaee S, O'Neill EJ, Barrat FJ, et al. (2004) IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J Immunol 172: 5986-5993.
8. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, et al. (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204: 1257-1265.
9. Bluestone JA, (2011) The yin and yang of interleukin-2-mediated immunotherapy. N Engl J Med 365: 2129-2131.
10. Weiss L, Donkova-Petrini V, Caccavelli L, Balbo M, Carbonneil C, et al. (2004) Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood 104: 3249-3256.
11. Kared H, Lelievre JD, Donkova-Petrini V, Aouba A, Melica G, et al. (2008) HIV-specific regulatory T cells are associated with higher CD4 cell counts in primary infection. AIDS 22: 2451-2460.
12. Bi X, Suzuki Y, Gatanaga H, Oka S, (2009) High frequency and proliferation of CD4+ FOXP3+ Treg in HIV-1-infected patients with low CD4 counts. Eur J Immunol 39: 301-309.
13. Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF, (2004) Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol 78: 2454-2459.
14. Kinter AL, Hennessey M, Bell A, Kern S, Lin Y, et al. (2004) CD25(+)CD4(+) regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4(+) and CD8(+) HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med 200: 331-343.
15. Shaw JM, Hunt PW, Critchfield JW, McConnell DH, Garcia JC, et al. (2011) Increased frequency of regulatory T cells accompanies increased immune activation in rectal mucosae of HIV-positive noncontrollers. J Virol 85: 11422-11434.
16. Belkaid Y, Rouse BT, (2005) Natural regulatory T cells in infectious disease. Nat Immunol 6: 353-360.
17. Fazekas de St Groth B, Landay AL, (2008) Regulatory T cells in HIV infection: pathogenic or protective participants in the immune response? AIDS 22: 671-683.
18. Hunt PW, Landay AL, Sinclair E, Martinson JA, Hatano H, et al. (2011) A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS One 6: e15924.
19. Sakaguchi S, Miyara M, Costantino CM, Hafler DA, (2010) FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10: 490-500.
20. Kaczmarek E, Koziak K, Sevigny J, Siegel JB, Anrather J, et al. (1996) Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem 271: 33116-33122.
21. Kukulski F, Levesque SA, Sevigny J, (2011) Impact of ectoenzymes on p2 and p1 receptor signaling. Adv Pharmacol 61: 263-299.
22. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, et al. (2007) Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110: 1225-1232.
23. Dwyer KM, Deaglio S, Gao W, Friedman D, Strom TB, et al. (2007) CD39 and control of cellular immune responses. Purinergic Signal 3: 171-180.
24. Pulte ED, Broekman MJ, Olson KE, Drosopoulos JH, Kizer JR, et al. (2007) CD39/NTPDase-1 activity and expression in normal leukocytes. Thromb Res 121: 309-317.
25. Fausther M, Lecka J, Soliman E, Kauffenstein G, Pelletier J, et al. (2012) Coexpression of ecto-5′-nucleotidase/CD73 with specific NTPDases differentially regulates adenosine formation in the rat liver. Am J Physiol Gastrointest Liver Physiol 302: G447-459.
26. Ohta A, Sitkovsky M, (2001) Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414: 916-920.
27. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, et al. (2004) Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 22: 657-682.
28. Ohta A, Madasu M, Kini R, Subramanian M, Goel N, et al. (2009) A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J Immunol 183: 5487-5493.
29. Moreno-Fernandez ME, Rueda CM, Rusie LK, Chougnet CA, (2011) Regulatory T cells control HIV replication in activated T cells through a cAMP-dependent mechanism. Blood 117: 5372-5380.
30. Nikolova M, Carriere M, Jenabian MA, Limou S, Younas M, et al. (2011) CD39/adenosine pathway is involved in AIDS progression. PLoS Pathog 7: e1002110.
31. Visovatti SH, Hyman MC, Bouis D, Neubig R, McLaughlin VV, et al. (2012) Increased CD39 nucleotidase activity on microparticles from patients with idiopathic pulmonary arterial hypertension. PLoS One 7: e40829.
32. Murayama A, Sakura K, Nakama M, Yasuzawa-Tanaka K, Fujita E, et al. (2006) A specific CpG site demethylation in the human interleukin 2 gene promoter is an epigenetic memory. Embo J 25: 1081-1092.
33. Porichis F, Kaufmann DE, (2011) HIV-specific CD4 T cells and immune control of viral replication. Curr Opin HIV AIDS 6: 174-180.
34. Younes SA, Yassine-Diab B, Dumont AR, Boulassel MR, Grossman Z, et al. (2003) HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med 198: 1909-1922.
35. Schulze Zur Wiesch J, Thomssen A, Hartjen P, Toth I, Lehmann C, et al. (2011) Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease. J Virol 85: 1287-1297.
36. Mandapathil M, Szczepanski MJ, Szajnik M, Ren J, Lenzner DE, et al. (2009) Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res 15: 6348-6357.
37. Airas L, Niemela J, Salmi M, Puurunen T, Smith DJ, et al. (1997) Differential regulation and function of CD73, a glycosyl-phosphatidylinositol-linked 70-kD adhesion molecule, on lymphocytes and endothelial cells. J Cell Biol 136: 421-431.
38. Klein M, Vaeth M, Scheel T, Grabbe S, Baumgrass R, et al. (2011) Repression of cyclic adenosine monophosphate upregulation disarms and expands human regulatory T cells. J Immunol 188: 1091-1097.
39. Liang B, Workman C, Lee J, Chew C, Dale BM, et al. (2008) Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 180: 5916-5926.
40. Thomson LF, Ruedi JM, Glass A, Moldenhauer G, Moller P, et al. (1990) Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol-anchored lymphocyte differentiation antigen ecto-5′-nucleotidase (CD73). Tissue Antigens 35: 9-19.
41. Yegutkin G, Bodin P, Burnstock G, (2000) Effect of shear stress on the release of soluble ecto-enzymes ATPase and 5′-nucleotidase along with endogenous ATP from vascular endothelial cells. Br J Pharmacol 129: 921-926.
42. Alam MS, Kurtz CC, Rowlett RM, Reuter BK, Wiznerowicz E, et al. (2009) CD73 is expressed by human regulatory T helper cells and suppresses proinflammatory cytokine production and Helicobacter felis-induced gastritis in mice. J Infect Dis 199: 494-504.
43. Zhang B, (2010) CD73: a novel target for cancer immunotherapy. Cancer Res 70: 6407-6411.
44. Jin D, Fan J, Wang L, Thompson LF, Liu A, et al. (2010) CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res 70: 2245-2255.
45. Erdmann AA, Gao ZG, Jung U, Foley J, Borenstein T, et al. (2005) Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood 105: 4707-4714.
46. Huang S, Apasov S, Koshiba M, Sitkovsky M, (1997) Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 90: 1600-1610.
47. Rickles RJ, Pierce LT, Giordano TP 3rd, Tam WF, McMillin DW, et al. (2010) Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies. Blood 116: 593-602.
48. Chern Y, Chiou JY, Lai HL, Tsai MH, (1995) Regulation of adenylyl cyclase type VI activity during desensitization of the A2a adenosine receptor-mediated cyclic AMP response: role for protein phosphatase 2A. Mol Pharmacol 48: 1-8.
49. Kammer GM, (1988) The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol Today 9: 222-229.
50. Averill LE, Stein RL, Kammer GM, (1988) Control of human T-lymphocyte interleukin-2 production by a cAMP-dependent pathway. Cell Immunol 115: 88-99.
51. Rahmouni S, Aandahl EM, Trebak M, Boniver J, Tasken K, et al. (2001) Increased cAMP levels and protein kinase (PKA) type I activation in CD4+ T cells and B cells contribute to retrovirus-induced immunodeficiency of mice (MAIDS): a useful in vivo model for drug testing. FASEB J 15: 1466-1468.
52. Aandahl EM, Aukrust P, Skalhegg BS, Muller F, Froland SS, et al. (1998) Protein kinase A type I antagonist restores immune responses of T cells from HIV-infected patients. FASEB J 12: 855-862.
53. Rauen T, Hedrich CM, Juang YT, Tenbrock K, Tsokos GC, (2011) cAMP-responsive element modulator (CREM)alpha protein induces interleukin 17A expression and mediates epigenetic alterations at the interleukin-17A gene locus in patients with systemic lupus erythematosus. J Biol Chem 286: 43437-43446.
54. Hedrich CM, Rauen T, Tsokos GC, (2011) cAMP-responsive element modulator (CREM)alpha protein signaling mediates epigenetic remodeling of the human interleukin-2 gene: implications in systemic lupus erythematosus. J Biol Chem 286: 43429-43436.
55. Bjorgo E, Tasken K, (2010) Novel mechanism of signaling by CD28. Immunol Lett 129: 1-6.
56. Moreno-Fernandez ME, Rueda CM, Velilla PA, Rugeles MT, Chougnet CA, (2012) cAMP During HIV Infection: Friend or Foe? AIDS Res Hum Retroviruses 28: 49-53.
57. Bopp T, Becker C, Klein M, Klein-Hessling S, Palmetshofer A, et al. (2007) Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med 204: 1303-1310.
58. Leal DB, Streher CA, Bertoncheli Cde M, Carli LF, Leal CA, et al. (2005) HIV infection is associated with increased NTPDase activity that correlates with CD39-positive lymphocytes. Biochim Biophys Acta 1746: 129-134.
59. Nigam P, Velu V, Kannanganat S, Chennareddi L, Kwa S, et al. (2010) Expansion of FOXP3+ CD8 T cells with suppressive potential in colorectal mucosa following a pathogenic simian immunodeficiency virus infection correlates with diminished antiviral T cell response and viral control. J Immunol 184: 1690-1701.
60. Navarro J, Punzon C, Jimenez JL, Fernandez-Cruz E, Pizarro A, et al. (1998) Inhibition of phosphodiesterase type IV suppresses human immunodeficiency virus type 1 replication and cytokine production in primary T cells: involvement of NF-kappaB and NFAT. J Virol 72: 4712-4720.
61. Sun Y, Li L, Lau F, Beavo JA, Clark EA, (2000) Infection of CD4+ memory T cells by HIV-1 requires expression of phosphodiesterase 4. J Immunol 165: 1755-1761.
62. Eltzschig HK, Ibla JC, Furuta GT, Leonard MO, Jacobson KA, et al. (2003) Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med 198: 783-796.
63. Kukulski F, Levesque SA, Lavoie EG, Lecka J, Bigonnesse F, et al. (2005) Comparative hydrolysis of P2 receptor agonists by NTPDases 1, 2, 3 and 8. Purinergic Signal 1: 193-204.